Table 2.
Univariate and multivariate analysis of serum creatinine elevation in patients treated with benmelstobart plus anlotinib (N = 264)
| N1 | Characteristics | N2 | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | ||||
| Age (years) | 95 | ≥ 65 vs. < 65 | 169 | 0.93 (0.56–1.57) | 0.7951 | 0.75 (0.43–1.33) | 0.3228 |
| Sex | 204 | Male vs. Female | 60 | 1.07 (0.59–1.94) | 0.8265 | 1.19 (0.62–2.25) | 0.6047 |
| BMI | 107 | ≥ 25 vs. < 25 | 157 | 1.54 (0.93–2.55) | 0.0953 | ||
| Hypertension | 116 | Yes vs. No | 148 | 1.22 (0.74–2.01) | 0.4342 | ||
| Diabetes | 38 | Yes vs. No | 226 | 2.03 (1.01–4.05) | 0.0455 | 2.01 (0.96–4.22) | 0.0634 |
| IMDC prognostic risk | 188 | Intermediate vs. Favourable | 37 | 0.67 (0.33–1.36) | 0.5507 | 0.81 (0.38–1.73) | 0.7967 |
| 39 | Poor vs. Favourable | 37 | 0.32 (0.12–0.85) | 0.0240 | 0.56 (0.19–1.65) | 0.3025 | |
| KPS | 62 | 70-80 vs. 90-100 | 202 | 1.14 (0.64–2.05) | 0.6503 | ||
| ECOG performance status | 192 | 1 vs. 0 | 72 | 1.21 (0.68–2.12) | 0.5176 | ||
| History of nephrectomy | 167 | Yes vs. No | 97 | 3.25 (1.84–5.75) | < 0.0001 | 2.22 (1.15–4.29) | 0.0177 |
| eGFR (mL/min/1.73 m²) | 74 | ≥ 90 vs. < 90 | 190 | 0.28 (0.15–0.54) | 0.0001 | 0.41 (0.20–0.85) | 0.0158 |
Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky performance status; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IQR, interquartile range; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval